Elephant Partners — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
Gila Therapeutics is a clinical-stage biotech company developing topical/lingual hormone therapies (starting with Topical Lingual PYY) that activate satiety centers in the brain via a tongue-brain neural pathway without systemic exposure.
BiotechDigital HealthLongevityMinneapolis, US
Christopher de Souza(Director)Thomas J. Vasicek(Executive Officer, Director, Promoter)Jon Freeman(Executive Officer)Richard Horan(Director)Donald R. Johns(Chief Medical Officer)
Board seatChristopher De Souza· per SEC Form D · $10M raise · filed Dec 2023
Atlanta, US
Jeremiah Daly(Director)Vu Lam(Executive Officer, Director)Josh Lieberman(Director)
Board seatJeremiah Daly· per SEC Form D · $28.1M raise · filed Jun 2021
Atlanta, US
Tippu Sulthan Gagguturu(Executive Officer, Director, Promoter)Christopher De Souza(Director)Jeremiah Daly(Director)Devender Reddy(Executive Officer)
Board seatJeremiah Daly· per SEC Form D · $15M raise · filed Jul 2021
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.